Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

GSK signs shingles vaccine deal with China’s Zhifei for around $3 billion

by Jessica Weisman-Pitts
0 comment
2023 10 06T063440Z 2 LYNXMPEJ9505O RTROPTP 4 GSK RESULTS

GSK signs shingles vaccine deal with China’s Zhifei for around $3 billion

By Maggie Fick and Andrew Silver

LONDON/SHANGHAI (Reuters) – China’s largest vaccines company Zhifei will pay British drugmaker GSK 2.5 billion pounds ($3.05 billion) for the exclusive rights to distribute GSK’s shingles vaccine in the world’s No.2 pharmaceuticals market.

The deal is one of a series of moves by western pharmaceutical firms to seize a bigger share of China’s market, including announcements from companies such as AstraZeneca.

The vaccine, named Shingrix, is GSK’s top-selling medicine. GSK said the deal with Zhifei is part of its efforts to more than double sales of Shingrix, to more than 4 billion pounds ($4.88 billion), by 2026.

In a call with journalists, GSK’s Chief Commercial Officer Luke Miels said Zhifei had an impressive track record of driving access to medicines in China, citing the company’s deal with drugmaker Merck & Co to distribute its Gardasil vaccine against human papillomavirus (HPV): “We essentially sought to replicate that with Shingrix.”

The deal will result in the vaccine being available in more than 30,000 locations across China, up from 9,500 currently. This is important, Miels said, because unlike in most countries, people can only access vaccines at these locations, and not at hospitals, doctors’ offices or health centres.

Zhifei will purchase volumes of Shingrix with a value to GSK worth 2.5 billion pounds over an initial three-year period, GSK said. GSK expects to extend beyond that three years, Miels said. The market for Shingrix in China, and also in Brazil and Mexico is “largely out-of-pocket”, and the vaccine’s launch in those markets is still in its early stages.

Miels said that Monday’s deal gives GSK more money to put into research and development, and “more room to concentrate” on the development of drugs in its pipeline, instead of distribution of them.


The agreement is set to start on Jan. 1. Zhifei shares were up as much as 20% to 58.40 yuan ($8.00) following the filing, their highest since March 27. GSK shares were up 1.2% by 0812 GMT, near their session high.

Shingrix is currently GSK’s biggest product and strongest growth driver, taking in 1.7 billion pounds in first-half sales, up 20% from a year prior.

JPMorgan analysts said in a note that the announcement “de-risks GSK’s Shingrix China sales for the next three years” and holds the potential for as much as a 6% upgrade to 2026 consensus Core EPS (Earnings per Share) forecasts.

GSK’s statement also said that Zhifei has granted it the “right of first refusal to be their exclusive partner for any co-development of an RSV vaccine for older adults in China”.

The company launched its respiratory syncytial virus (RSV)vaccine, called Arexvy, in the United States after it was approved by regulators in May.

Barclays analysts said in a note last month that the first five weeks of prescription data showed that the vaccine’s launch was off to a strong start and that GSK appeared to have the lead over Pfizer’s competing vaccine for RSV.

A GSK shareholder then told Reuters that if the strong start was maintained through September, it would mean consensus estimates for 2023 sales of Arexvy, at about 215 million pounds, are “way too low”.

GSK is banking on Arexvy being its next blockbuster medicine, part of its efforts to ensure growth as it faces a combination of patent expiries and declining revenue from its current bestsellers by the end of this decade.


(This story has been refiled to remove the extraneous ‘pound’ in paragraph 1)


($1 = 0.8192 pounds)

($1 = 7.2960 Chinese yuan renminbi)


(Reporting by Maggie Fick in London and Andrew Silver in Shanghai, additional reporting by Eva Mathews in Bengaluru and Lucy Raitano in London; Editing by Savio D’Souza and Louise Heavens, Kirsten Donovan)